AIM Immunotech Inc. (formerly Hemispherx Biopharma, Inc.) — Form 10-Q Summary
Business context and reporting period
The filing covers the quarter ended March 31, 2014. The company develops immune-based therapies. Its lead candidate, Ampligen, remained investigational; Alferon N Injection was approved for a limited indication, but commercial sales were halted pending renewed production and FDA review.
Financial performance and liquidity
| Metric | Q1 2014 | Q1 2013 / prior date |
|---|---|---|
| Revenue | $76,000 | $42,000 |
| Operating loss | $5.112 million | $4.562 million |
| Net loss | $3.836 million | $3.611 million |
| Net loss per share | $0.02 | $0.02 |
| Net cash used in operations | $2.895 million | $5.851 million |
| Cash, cash equivalents and marketable securities | $21.554 million at March 31 | $18.194 million at December 31, 2013 |
Revenue came from the Ampligen cost-recovery/open-label treatment program; the company reported no Alferon finished goods available for commercial sale. Total costs and expenses were $5.188 million, including $323,000 of production costs, $2.326 million of R&D, and $2.539 million of G&A. The filing does not provide a meaningful product gross-margin measure given the limited revenue and production-cost presentation.
Cash from operations improved year over year, partly because Q1 2013 included approximately $2.196 million of employee and consultant bonus payments. Investing activities used $177,000; financing provided $6.374 million, principally from $6.385 million in net ATM share-sale proceeds. The company had $4.105 million cash and $17.449 million in marketable securities. Total liabilities were $3.017 million, including $46,000 of capital lease obligations and $14,000 of redeemable warrants. The margin-account loan balance was zero. Accumulated deficit was $264.155 million.
Changes versus the prior comparable period
- Net loss increased $225,000, or about 6%, despite a $440,000 increase in proceeds recognized from selling New Jersey tax-loss carryforwards. Higher production costs, G&A, and the absence of the prior-year $89,000 warrant-valuation gain also affected the comparison.
- Revenue rose $34,000, or 81%, primarily as the number of patients in the cost-recovery program increased.
- R&D was nearly unchanged. G&A increased $462,000, or 22%, with higher legal fees and executive incentive compensation among the cited drivers.
- The company sold 14.47 million shares through its ATM program in Q1 for $6.385 million net proceeds. Weighted-average shares outstanding rose to 176.7 million from 166.8 million.
Outlook, management commentary, and risks
- No earnings or revenue guidance was provided. Management said additional financing may be needed; future funding is not assured and equity financing could dilute shareholders. Management also stated that the planned Ampligen studies and related FDA work exceed current financial resources without additional funding.
- The FDA’s February 2013 Complete Response Letter declined to approve Ampligen for chronic fatigue syndrome and called for at least one additional clinical trial, nonclinical studies, and data analyses. Management estimated a new well-controlled study could take approximately 18 months to three years after design acceptance; cost and timing remained uncertain.
- Alferon manufacturing upgrades and validation were ongoing. Management estimated newly produced API would take approximately 16 months to be ready for submission to the FDA, with facility inspection, manufacturing reaffirmation, and product release still required. Existing older inventory was not expected to be submitted for commercial release.
- The Ampligen supply agreement with Hollister-Stier expired March 11, 2014; the company was working toward an extension that could involve additional fees. The Alferon LDO Phase II study remained delayed as resources were directed to facility upgrades.
- Clinical and commercial outcomes depend on regulatory approval, successful studies, manufacturing validation, and market acceptance. The filing also identifies reliance on outside manufacturers and suppliers, limited commercial revenue, potential financing constraints, and significant competition as risks.
- Several securities and shareholder derivative cases remained pending; the company reported it could not estimate likely outcomes and had recorded no loss contingency. A former CFO’s employment-related suit was also being contested. Separately, a jury returned a verdict for the company in the MidSouth case, and the judgment became final.
Important facts for investors to verify
- Current cash burn, liquidity runway, and the company’s ability to fund the additional Ampligen studies and regulatory work.
- Progress and FDA requirements for the Ampligen NDA, including study design, scope, timing, and financing.
- Completion of Alferon facility validation, inspection, production, and FDA review; the filing’s 16-month estimate is not a guarantee of commercial restart.
- ATM issuance capacity, subsequent share sales, and dilution; 183,853,828 common shares were outstanding on April 25, 2014.
- Resolution and potential financial impact of the pending legal proceedings and the expired Ampligen supply agreement.